Table of Content

1. Introduction
1.1. Market Definition
1.2. Markets Covered
1.3. Years Considered for the Study
1.4. Currency
1.5. Key Stakeholders


2. Research Methodology
2.1. Research Methodology Steps
2.2. Secondary and Primary Research Methodology
2.2.1. Secondary Research
2.2.1.1. Key Data from Secondary Sources
2.2.2. Primary Research
2.2.2.1. Key Data from Primary Sources
2.2.2.2. Key Insights from Primary Sources
2.3. Market Size Estimation Methodology
2.4. Market Forecast Methodology
2.5. Market Breakdown and Data Triangulation


3. Coronavirus: Epidemiology
3.1. About Coronavirus
3.2. Transmission & Symptoms
3.3. Prevention
3.4. Epidemiology


4. Executive Summary
4.1. Introduction
4.2. Global Economic Impact
4.3. COVID-19 Response
4.4. COVID-19 Research Pipeline
4.5. COVID-19 Pipeline Development Challenges
4.6. Key Companies


5. Covid-19: Impact on Healthcare Industry
5.1. Introduction
5.2. Key Trends & Impact on Healthcare Subsegments
5.3. Diagnostics
5.3.1. PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
5.3.1.1. Advantages Offered by PCR Testing in COVID -19 Diagnosis
5.3.1.2. Restraints
5.3.1.3. Key Companies
5.3.2. Antibody Testing / Serological Testing
5.3.2.1. Advantages Over Molecular Tests
5.3.2.2. Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
5.3.2.3. Restraints
5.3.2.4. Key Companies
5.4. Therapies
5.4.1. Vaccines
5.4.2. Immunotherapies (Antibodies)
5.4.2.1. Monoclonal Antibody
5.4.2.2. T-Cell Therapy
5.4.2.3. Potential Game Changers: Antibodies
5.4.2.3.1. Ilaris (Canakinumab)
5.4.2.3.2. Sylvan (Siltuximab)
5.4.2.3.3. Lenzilumab
5.4.2.3.4. Ultomiris (Ravulizumab-CWVZ)
5.4.2.3.5. Tocilizumab
5.4.3. Antivirals
5.4.3.1. Potential Game Changers
5.4.3.1.1. Chloroquine and Hydroxychloroquine (HCQ)
5.4.3.1.2. Remdesivir
5.4.4. Cell-Based Therapies
5.4.5. Other Therapies
5.4.5.1. Plasma Therapy
5.4.5.2. Devices


6. Geography Impact Assessment
6.1. Introduction
6.1.1. Global Virtual Fund-Raising Event to Raise USD 8 Billion for Coronavirus Vaccine
6.2. North America
6.2.1. COVID-19 Impact on the U.S. Economy
6.2.2. Significant R&D Investment by the U.S. Government for COVID-19 Treatment
6.2.3. High Dependence on the U.S. on Drugs Import Expected to Create Drug Shortages
6.2.4. Investments by Coalition for Epidemic Preparedness Innovations (CEPI) and Canadian Government
6.2.5. Canada Announced Investment of USD 192 Million on Vaccine Development as Well as Partnering with Industry and Academics
6.2.6. Creation of SARS-COV2 Vaccine-Bank by Researchers in Canada
6.3. Europe
6.3.1. Economic Impact of COVID-19: European Nations
6.3.2. European Firms to Lead the COVID-19 Treatment Researches
6.3.3. U.K. at Forefront in Drug Development Researches to Fight Covid-19
6.3.4. Partnership of European Pharmaceutical Giants – Sanofi and GSK To Develop COVID-19 Vaccine
6.3.5. German Vaccine Became the First European MRNA Vaccine to Enter Human Testing
6.3.6. Growing Interest of Billionaire in German Drug Development for COVID-19
6.4. APAC
6.4.1. Economic Impact of COVID-19: APAC
6.4.2. Asian Countries Leading the Diagnostics Test Commercialization
6.4.3. India In Favourable Position for Future Production Of COVID-19 Vaccine
6.4.4. Chinese Lockdown to Negatively Impact the Drugs Supply Chain
6.5. Rest of the World
6.5.1. Government Initiatives to Support COVID-19 Medicine Research & Other Drug Supply in Brazil
6.5.2. Saudi Arabia to Invest USD 2 Billion in Coronavirus Vaccine Development
6.5.3. Government Initiatives to Support Rapid Development of COVID-19 Therapy in South Africa


7. Competitive Landscape
7.1. Introduction
7.2. Agreements/Deals/Partnerships/Collaborations/Joint Ventures
7.3. R&D Updates
7.4. Auhrozation / Approvals
7.5. Donations Made
7.6. Funding Received
7.7. Capacity Expansion
7.8. Other Growth Strategies


8. Company Updates
8.1. Company Segmentation
8.2. Diagnostic Companies
8.2.1. Roche Holding Ag
8.2.1.1. About the Firm
8.2.1.2. COVID-19 Pipeline
8.2.1.3. Recent Developments
8.2.2. Thermo Fisher Scientific, Inc.
8.2.2.1. About the Firm
8.2.2.2. COVID-19 Pipeline
8.2.2.3. Recent Developments
8.2.3. Becton, Dickinson and Company
8.2.3.1. About the Firm86
8.2.3.2. COVID-19 Pipeline
8.2.3.3. Recent Developments
8.2.4. Abbott Laboratories
8.2.4.1. About the Firm
8.2.4.2. COVID-19 Pipeline
8.2.4.3. Recent Developments
8.2.5. Cepheid (Subsidiary of Danaher Corporation)
8.2.5.1. About the Firm
8.2.5.2. COVID-19 Pipeline
8.2.5.3. Recent Developments
8.3. Antivirals
8.3.1. Abbivie Corporation
8.3.1.1. About the Firm
8.3.1.2. COVID-19 Pipeline
8.3.1.3. Recent Developments
8.3.2. Gilead Sciences, Inc.
8.3.2.1. About the Firm
8.3.2.2. Covid-19- Pipeline
8.3.2.3. Recent Developments
8.3.3. Eli Lilly And Company
8.3.3.1. About the Firm
8.3.3.2. Covid-19- Products
8.3.3.3. Recent Developments
8.4. Vaccine Developers
8.4.1. Moderna, Inc.
8.4.1.1. About the Firm
8.4.1.2. COVID-19 Pipeline
8.4.1.3. Recent Developments
8.4.2. Novavax, Inc
8.4.2.1. About the Firm
8.4.2.2. COVID-19 Pipeline
8.4.2.3. Recent Developments
8.4.3. Medicago, Inc
8.4.3.1. About the Firm
8.4.3.2. COVID-19 Pipeline
8.4.3.3. Recent Developments
8.4.4. Inovio Pharmaceuticals, Inc.
8.4.4.1. About the Firm
8.4.4.2. COVID-19 Pipeline
8.4.4.3. Recent Developments
8.4.5. GlaxoSmithKline (GSK)
8.4.5.1. About the Firm
8.4.5.2. COVID-19 Pipeline
8.4.5.3. Recent Developments
8.4.6. Sanofi S.A.
8.4.6.1. About the Firm
8.4.6.2. COVID-19 Pipeline
8.4.6.3. Recent Developments
8.4.7. Johnson & Johnson
8.4.7.1. About the Firm
8.4.7.2. COVID-19 Pipeline
8.4.7.3. Recent Developments
8.5. Immunotherapy Firms
8.5.1. Sorrento Therapeutics, Inc.
8.5.1.1. About the Firm
8.5.1.2. COVID-19 Pipeline
8.5.1.3. Recent Developments
8.5.2. Astrazeneca Plc
8.5.2.1. About the Firm
8.5.2.2. COVID-19 Pipeline
8.5.2.3. Recent Developments
8.5.3. Pfizer, Inc.
8.5.3.1. About the Firm
8.5.3.2. COVID-19 Pipeline
8.5.3.3. Recent Developments
8.5.4. Cti Biopharma Corporation
8.5.4.1. About the Firm
8.5.4.2. COVID-19 Pipeline
8.5.4.3. Recent Developments
8.5.5. Oncoimmune, Inc.
8.5.5.1. About the Firm
8.5.5.2. COVID-19 Pipeline
8.5.5.3. Recent Developments
8.6. Cell-Based Therapy
8.6.1. Athersys, Inc.
8.6.1.1. About the Firm
8.6.1.2. COVID-19 Pipeline
8.6.1.3. Recent Developments
8.6.2. Cellularity, Inc.
8.6.2.1. About the Firm
8.6.2.2. COVID-19 Pipeline
8.6.2.3. Recent Developments
8.6.3. Pluristem Therapeutics, Inc.
8.6.3.1. About the Firm
8.6.3.2. COVID-19 Pipeline
8.6.3.3. Recent Developments
8.7. Plasma Therapy
8.7.1. Takeda Pharmaceutical Company Ltd
8.7.1.1. About the Firm
8.7.1.2. COVID-19 Pipeline
8.7.1.3. Recent Developments

List of Tables

Table 1 Health & Life Sciences Market Opportunity Assessment Post COVID-19, by Product Type, 2019–2025 ($Million)
Table 2 Industry Trend & Impact Analysis on Healthcare Sub-Sectors Post COVID-19
Table 3 Diagnostics Market Opportunity for COVID-19, by Product Type, 2019–2025 ($Million)
Table 4 Diagnostics Market Opportunity for COVID-19, by Geography, 2019–2025 ($Million)
Table 5 PCR Cycle and Corresponding No. of Target Copies Produced
Table 6 PCR Testing Market Opportunity for COVID-19, by Geography, 2019–2025 ($Million)
Table 7 Antibody Testing Market Opportunity Assessment for COVID-19, by Geography, 2019–2025 ($Million)
Table 8 Therapy Market Opportunity Assessment for COVID-19, by Product Type, 2019–2025 ($Million)
Table 9 Therapy Market Opportunity Assessment for COVID-19, by Geography, 2021–2025 ($Million)
Table 10 Key Vaccine Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
Table 11 Vaccines Market Opportunity for COVID-19, by Geography, 2021–2025 ($Million)
Table 12 Immunotherapy Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
Table 13 Immunotherapy Market Opportunity for COVID-19, by Geography, 2021–2025 ($Million)
Table 14 Antiviral Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
Table 15 Antiviral Market Opportunity for Covid-19, by Geography, 2021–2025 ($Million)
Table 16 Cell-Based Therapy Pipeline for COVID-19 (Non-Exhaustive, As of May 05, 2020)
Table 17 Cell Based Therapy Market Opportunity for COVID-19, by Geography, 2021–2025 ($Million)
Table 18 Plasma Therapies in Pipeline for COVID-19
Table 19 COVID-19 Devices Platforms in Pipeline
Table 20 Other Therapies Market Opportunity for COVID-19, by Geography, 2021–2025 ($Million)
Table 21 Life Sciences Products Market for COVID-19, by Geography, 2019–2025 ($Million)
Table 22 COVID-19 Treatment Investments, by BARDA (U.S.)
Table 23 North America: COVID-19 Health & Life Sciences Market Opportunity, 2019–2025 ($Million)
Table 24 North America: Diagnostics Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 25 North America: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 ($Million)
Table 26 Key Economic Indicators: Europe (2019 – 2021)
Table 27 Europe: Health & Life Sciences Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 28 Europe: COVID-19 Diagnostics Market Opportunity, 2019–2025 ($Million)
Table 29 Europe: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 ($Million)
Table 30 Key Economic Indicators: Asia (2019 – 2021)
Table 31 APAC: Health & Life Sciences Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 32 APAC: Diagnostics Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 33 APAC: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 ($Million)
Table 34 RoW: Health & Life Sciences Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 35 RoW: Diagnostics Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 36 RoW: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 ($Million)

List of Figures

Figure 1 Research Methodology
Figure 2 Market Size Estimation Methodology: Bottom-Up Approach
Figure 3 Market Size Estimation Methodology: Top-Down Approach
Figure 4 Research Design
Figure 5 Data Triangulation Methodology
Figure 6 Global Coronavirus Cases, As of 15 May 2020
Figure 7 GDP Trend Across the U.S., U.K., Germany, China, and India (2019, 2020 (F), and 2021 (F))
Figure 8 COVID-19 Treatment Pipeline, by Development Stage (As of May 2020)
Figure 9 Life Sciences Market Segmentation Impacted by Covid-19
Figure 10 COVID-19 Treatment Pipeline in Development, by type and Development Stage
Figure 11 Vaccine Pipeline, by Category & Development Stage
Figure 12 Immunotherapy / Antibodies Pipeline, by Development Stage (As of May 2020)
Figure 13 Antiviral Pipeline, by Development Stage (As of May 2020)
Figure 14 Cell-Based Therapy Pipeline, by Development Stage (As of May 2020)
Figure 15 Key Economic Indicators: U.S. (2018 To April 2020 & Forecast to 2021)
Figure 16 Key Growth Strategies, by Development & by Company, Feb – May 2020
Figure 17 Key Firms Active in COVID-19 Product Development